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persistently high levels of survivin in early
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Introduction: High levels of the oncoprotein survivin may be detected in the majority of patients with early
rheumatoid arthritis (RA). Survivin is a sensitive predictor of joint damage and persistent disease activity. Survivin-positive
patients are often poor responders to antirheumatic and biological treatment. The aim of this study was to investigate
the reproducibility of survivin status and its significance for clinical and immunological assessment of RA patients.
Methods: Survivin levels were measured in 339 patients from the Better Anti-Rheumatic FarmacOTherapy (BARFOT)
cohort of early RA at baseline and after 24 months. The association of survivin status with joint damage (total Sharp-van
der Heijde score), disease activity (Disease Activity Score based on evaluation of 28 joints (DAS28)), functional disability
(Health Assessment Questionnaire (HAQ)), and pain perception (Visual Analogue Scale (VAS)) was calculated in the
groups positive and negative for survivin on both occasions, and for the positive-negative and negative-positive
groups.
Results: In 268 patients (79%) the levels of survivin were similar at baseline and after 24 months, 15% converted from
survivin-positive to survivin-negative, and 5% from survivin-negative to survivin-positive. A combination of smoking and
antibodies against cyclic citrullinated peptides (aCCP) predicted persistently (baseline and 24 months) high levels of survivin
(odds ratio 4.36 (95% CI: 2.64 to 7.20), P< 0.001), positive predictive value 0.66 and specificity 0.83). The independent nature
of survivin and aCCP was demonstrated by statistical and laboratory analysis. Survivin positivity on both test occasions was
associated with the progression of joint damage, significantly higher DAS28 and lower rate of remission at 24 and 60
months compared to negative-negative patients. Survivin status was less associated with changes in HAQ and VAS.
Conclusions: Survivin is a relevant and reproducible marker of severe RA. Persistently high levels of survivin were
associated with smoking and the presence of aCCP and/or RF antibodies and predicted persistent disease activity and joint
damage.Introduction
The course of rheumatoid arthritis (RA) may vary con-
siderably, from early and long-lasting remission to per-
sistent disabling joint damage [1,2]. Early efficient
antirheumatic treatment and tight follow-up have been a
successful strategy to postpone disability. Identifying the
patients with urgent need for antirheumatic treatment
continues to be challenging. Reliable predictors of the* Correspondence: maria.bokarewa@rheuma.gu.se
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reproduction in any medium, provided the ordisease progress and outcome assist clinicians to make
the decision to choose and start antirheumatic treat-
ment. Several models designed to predict the course of
RA have recently been proposed. These models include
ultrasound [3] and radiometric [4] evaluation of joints
and a combination of genetic and environmental vari-
ables [5]. Serological markers remain a sensitive and reli-
able way of quick screening of broad patient cohorts.
Antibodies against cyclic citrullinated peptides (aCCPs)
and antibodies against the Fc domain of immunoglobu-
lins (rheumatoid factor (RF)) are currently used to iden-
tify patients with a high probability of developingal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical and demographic baseline characteristics
of rheumatoid arthritis patientsa
Patient demographics (N = 339) Level and frequency
Age, years 56.5 ± 16
Women 224 (66%)
Disease duration, months 6.2 ± 3.3
RF+ 184 (55%)
aCCP+ 169 (49%)
DAS28 5.6 ± 1.26
VAS pain, mm 45 ± 24
HAQ 1.00 ± 0.66








Combination of DMARDs 3 (1%)
No DMARDs 51 (15%)
Prednisolone 210 (62%)
aaCCP+, positive for antibodies against cyclic citrullinated peptides; DAS28,
Disease Activity Score based on evaluation of 28 joints; DMARD, disease-
modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; MTX,
methotrexate; RF+, rheumatoid factor–positive; SHS, Sharp-van der Heijde
score; SLZ, sulphasalazine; VAS, Visual Analogue Scale. The values are mean ±
SD or n (%) unless otherwise stated.
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predictive ability in individual patients is hampered by
limited specificity.
We have recently found that RA patients with high
levels of oncoprotein survivin in serum and synovial
fluid have persistent joint inflammation and damage
[10]. The proportion of survivin-positive patients may
vary between 60% in patients with early RA [11] and
28% in patients with established RA undergoing treat-
ment [10]. Survivin is a multifunctional protein that
regulates cell proliferation and supports cell cycle pro-
gression and resistance to apoptosis [12]. In the rheuma-
toid synovia, survivin has been found at the sites of
accumulation of macrophages and memory T cells in the
inflamed tissues and in association with the transition to
an invasive phenotype of synovial fibroblasts [13-15]. As
a consequence of these cellular events, survivin may help
to identify patients with early RA at risk of developing
joint damage [11]. The results obtained in an independ-
ent cohort of RA patients showed that survivin was as-
sociated with a therapy-resistant course of arthritis, poor
response to biological treatment [16] and a low remis-
sion rate [11]. Survivin is frequently found in conjunc-
tion with aCCPs and RF, and the combination of
survivin with these autoantibodies enhances the predict-
ive power of survivin.
The present study addresses the question of reproduci-
bility of survivin status in consecutive tests of RA pa-
tients and the value of repeated survivin testing for
prediction of joint damage, persistence of disease activ-
ity, functional disability and pain.
Methods
Patient cohort
A total of 339 patients with early RA (66% women, mean
age 56.5 years, 55% RF-positive and 49% aCCP-positive)
and a disease duration of 1 year or less were consecu-
tively included into a multicentre observational study
(the Better Anti-Rheumatic FarmacOTherapy (BARFOT)
project) [7] between September 1993 and December
1999. All the patients fulfilled the classification criteria
for RA established by the American Rheumatism Associ-
ation [17]. No patient had received prior disease-
modifying antirheumatic drug (DMARD) or prednisol-
one treatment for their RA. At the time of inclusion,
each patient’s smoking history was recorded and defined
as current, previous or never-smoker. Clinical and
laboratory assessments of the patients were performed
at the time of inclusion into the study (baseline) and
thereafter at 6, 12, 24 and 60 months of follow-up. Radi-
ography was performed at the time of inclusion and
thereafter at 12, 24 and 60 months. The baseline data
are presented in Table 1. All patients gave their informed
consent and the ethics committees at KarolinskaUniversity Hospital, Lund University Hospital, Sahlgrenska
University Hospital in Gothenburg and Linköping Univer-
sity Hospital approved the study. Disease activity was mea-
sured on the basis of the Disease Activity Score based on
evaluation of 28 joints (DAS28) [18]. Remission was de-
fined as DAS28 <2.6 (European League Against Rheuma-
tism criteria) [19]. Functional disability was assessed using
a Swedish version of the Stanford Health Assessment
Questionnaire (HAQ) [20]. Pain perception was assessed
on a Visual Analogue Scale (VAS) with a range from 0 to
100 mm.
Laboratory analyses
Serum samples were collected at the time of inclusion
into the study and after 24 months and stored at −70°C
until further analyses. The levels of survivin were mea-
sured by performing a sandwich enzyme-linked im-
munosorbent assay (ELISA) (DYC647; R&D Systems,
Abingdon, UK). Values of circulating survivin above
300 pg/ml, corresponding to 3 standard deviations over
the mean level of a healthy control group, were defined
as positive [10]. RF was analysed using the SERODIA-
RA rheumatoid factor agglutination test (Fujirebio,
Table 2 Individual measurements of survivin, rheumatoid
factor and antibodies against cyclic citrullinated peptides
in the randomly selected serum samples used for




RF (IU/ml) CCP (IU/ml) Survivin (ng/ml)
Mean Mean Mean
A
RF− 1 0 0 0 0 7.45 20.3
aCCP− 2 0 0 40.7
Surv+ 3 0 0 35.4
4 0 0 8.07
5 0 0 9.95
B
RF+ 6 160 120 0 0 0 0
aCCP− 7 83 0 0
Surv− 8 240 0 0
9 65 0 0
10 50 0 0
C
RF+ 11 160 202 480 534 0 0
aCCP+ 12 140 590 0
Surv− 13 220 51 0
14 390 48 0
15 100 1500 0
D
RF− 16 0 0 0 0 0 0
aCCP− 17 0 0 0
Surv− 18 0 0 0
19 0 0 0
20 0 0 0
aaCCP, antibodies against cyclic citrullinated peptide; RF, rheumatoid factor;
Surv, survivin.
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>20 IU/ml. aCCPs were detected by ELISA (anti-CCP2
antibody kit; Euro Diagnostica AB, Malmö, Sweden),
positive aCCP was defined as >25 IU/ml.
Technical evaluation of survivin by ELISA for potential
interference of autoantibodies
Twenty randomly chosen serum samples with known
levels of survivin, RF and aCCP were used to prepare a
survivin-positive pool (pool A), a RF-positive pool (pool
B), a RF- and aCCP-positive pool (pool C) and a negative
pool (pool D) (Table 2). The following experimental pro-
cedures were carried out: serial dilution of pool A to test
recovery of survivin levels with sample dilution; a mix-
ture procedure whereby pool A (survivin-positive) was
diluted with pool B (RF-positive); and a spike recovery
procedure whereby pool D (negative), pool B (RF-posi-
tive) and pool C (RF- and aCCP-positive) were spiked
with recombinant survivin (10 ng/ml, 5 ng/ml, 2.5
ng/ml, 1.25 ng/ml and 0 ng/ml).
Radiographic measurements
Posteroanterior radiographs of the hands and feet were
obtained at the time of study entry from all 339 patients,
at 24 months from 337 patients and at 60 months from
296 patients. Radiographic joint damage was assessed on
the basis of the Sharp-van der Heijde score (SHS) [21].
The films were read by one of two experienced readers
as previously described [11]. Double-readings of a frac-
tion of films showed good agreement between the two
readers. For 49 such double-readings of baseline and
5-year films, the smallest detectable change (SDC) could
be calculated by defining radiological progression as a >5.4
change in the total SHS score over the course of 5 years.
Radiographic progression was defined as a >5.4 change in
total SHS over the course of 60 months, the SDC.
Statistical analysis
Statistical analyses were performed using SPSS version
21.0 statistical software (SPSS, Chicago, IL, USA). To
test the differences between groups, the Mann–Whitney
U test, the Kruskal–Wallis test and the Wilcoxon
signed-rank test for paired analysis were used for con-
tinuous variables, and the χ2 test was used for propor-
tions. When an overall significance was obtained by the
Kruskal–Wallis test, pairwise post hoc analyses were
calculated using SPSS software (nonparametric tests of
two or more independent samples). Spearman’s rank
correlation coefficient was used to assess the relation-
ships between two continuous variables. All significance
tests were two-tailed and conducted at the 0.05 level of
significance. Univariate analyses of the association of
survivin and other baseline clinical and demographic
variables with radiological and clinical outcomes wereperformed. The predictive performance of survivin was
analysed by 2 × 2 tables and odds ratios (ORs), sensitiv-
ity, specificity, positive predictive value (PPV) and nega-
tive predictive value were calculated.
Results
Variability of survivin status over 24 months
The levels of survivin were measured in the paired
serum samples of 339 patients at the first visit to a
rheumatologist (baseline) and 24 month later. The abso-
lute levels of survivin in the total material changed from
0.95 ng/ml (0 to 4.3) at baseline to 0.22 ng/ml (0 to 2.5)
at 24 months (median (IQR); P < 0.001). Survivin-
positive samples (>0.3 ng/ml) comprised 56.6% (192 of
339 patients) of the baseline samples and 46.3% (157 of
339 patients) of the samples taken 24 months later.
Survivin status at baseline was similar to that at baseline
in 79% of samples taken at 24 months, referred to below
as positive-positive and negative-negative groups, re-
spectively. The absolute values of the positive-positive
group tended to be lower after 24 months (P = 0.057)
Figure 1 Absolute serum levels of survivin, rheumatoid factor
and antibodies against cyclic citrullinated peptide in the
rheumatoid arthritis patients. The levels of survivin were measured
in 339 patients from the Better Anti-Rheumatic FarmacOTherapy
(BARFOT) cohort of early rheumatoid arthritis at baseline and after 24
months. The patients were divided into four groups based on their
survivin status at those two occasions indicated as positive-positive
(n = 139), positive–negative (n = 53), negative–positive (n = 18) and
negative-negative (n = 129). (A) The absolute levels of survivin are
shown at baseline and 24 months. The concentration >0.3 ng/ml
indicates high survivin levels (shown as a dashed line). The absolute
levels of rheumatoid factor (RF) (IU/ml) (B) and cyclic citrullinated
peptide (CCP) (IU/ml) (C) are shown at baseline. Data are shown as
IQRs with the medians indicated by lines. (D) The frequency of
autoantibodies (RF and antibodies against CCP (aCCP)) within each
patient group is shown (%). The Wilcoxon signed-rank test was used
for comparison of survivin levels at baseline and 24 months.
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negative occurred in 53 samples (15.6%), defined as posi-
tive–negative, and 18 (5.3%) of the samples negative for
survivin at baseline converted to positive 24 months
later. The latter samples are referred to below as nega-
tive–positive.
The changes in survivin status occurred equally often
in the patients treated with methotrexate or sulpha-
salazine as in those not treated with DMARDs. The
change in survivin status occurred independently of
treatment with low-dose oral prednisolone. Thus, we
observed no relationship between survivin status and
treatment started at baseline. At 24 months, the posi-
tive-positive patients were significantly more often on
DMARD treatment including combination of two or
more DMARDs compared to the negative-negative pa-
tients (81.3% vs 50.4%, p = 0.001).
Predictive role of autoantibodies and smoking on survivin
status
Positivity for survivin at baseline was associated with
cigarette smoking status in 71% of current smokers, 56%
of previous smokers and 49% of never smokers (overall
P = 0.004). The OR for survivin positivity at baseline was
significantly higher in the patients who had ever smoked
compared to nonsmokers (OR 1.79 (95% CI 1.16 to
2.76); P = 0.009). A change in survivin status occurred
equally as often in smokers as in nonsmokers.
The ability of smoking, aCCP and RF to predict the per-
sistence of survivin positivity was assessed. It was found
that survivin positivity persisted more frequently in pa-
tients who had ever smoked than in nonsmokers (OR 1.81
(95% CI 1.17 to 2.81); P = 0.008). Furthermore, survivin
positivity on both test occasions was also more common in
the patients who were aCCP-positive and/or RF-positive
compared with the rest of the patients (OR 15.56 (95% CI
8.06 to 30.02); P < 0.001). Similarly, survivin persistence
was more common in the aCCP-positive (OR 8.89 (95% CI
5.32 to 14.87); P < 0.001) and RF-positive patients (OR
14.67 (95% CI 8.14 to 26.44); P < 0.001). Patients with a his-
tory of smoking combined with the presence of aCCP were
more often survivin-positive on both test occasions than
the rest of the patients (OR 4.36 (95% CI 2.64 to 7.20);
P < 0.001). This was also the case for patients with a history
of smoking combined with aCCP and/or RF positivity
(OR 4.60 (95% CI 2.85 to 7.45); P < 0.001). These data indi-
cate that smoking status and the presence of aCCP and/or
RF have an additive value for predicting persistently high
levels of survivin in RA patients.
Accuracy of ELISA for survivin in presence of
autoantibodies
The presence of autoantibodies (RF and aCCP) was
detected in a significant number of survivin-positivesamples (Figure 1D) on the basis of absolute values
(in IU/ml) of RF (Figure 1B) and aCCP (Figure 1C),
and correlation between these biological markers was
noted (survivin/aCCP: Spearman’s ρ = 0.59, survivin/RF:
Spearman’s ρ = 0.72, aCCP/RF: Spearman’s ρ = 0.65;
P < 0.001 for each pair). In a logistic regression model in
our previous article [11], survivin and aCCP, but not RF,
were independent predictors of radiological progression,
whereas RF did not. When we repeated this calculation
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similar results (survivin: OR 2.28 (95% CI 0.99 to 5.23),
P < 0.052; aCCP: OR 5.72 (95% CI 2.36 to 13.86),
P < 0.001; RF: OR 0.69 (95% CI 0.26 to 1.82), P = 0.45).
Potential interference of autoantibodies in the meas-
urement of survivin levels was addressed. First, we stud-
ied the recovery of survivin levels using serial dilution of
pooled samples with known concentrations of survivin
(pool A). The recovery of survivin measurements
was 98% of the expected concentration (Figure 2A). In
the second step, a mixing procedure was performed
whereby the survivin-positive pool was diluted with RF-
positive pool, which produced increasing concentrations
of RF with each dilution. The resulting concentrations
did not differ from the parallel samples without RF
(Figure 2B), and the recovery of survivin measurements
was 98%. Third, a spike recovery procedure was used
whereby pool B (RF-positive) and pool C (RF- and
aCCP-positive) and pool D (RF- and aCCP-negative)
were spiked with predetermined concentrations of re-
combinant survivin between 0 and 10 ng/ml. Levels of
survivin measured in each pooled sample showed the
recovery of 85% to 100% in the different concentrationsFigure 2 Evaluation of potential interference of autoantibodies with m
serum samples with known levels of survivin (Surv), rheumatoid factor (RF)
to prepare a survivin-positive pool (pool A), a RF-positive pool (pool B), a R
(pool D). Serial dilution of pool A showed 98% recovery of survivin levels w
B (RF-positive). The measurements of survivin were not affected by these in
pool D (RF- and aCCP-negative), pool B (RF–positive and aCCP-negative) an
survivin. The measurements of survivin showed 85% to 100% recovery, whtested (Figure 2D). Taken together, the experimental
procedures proved the accuracy of survivin measure-
ments in samples containing autoantibodies (RF and/or
aCCP).
Radiographically detected joint damage and progression
Our previous study showed that survivin positivity at
baseline strongly predicted the development and pro-
gression of joint damage [11]. In our present study, we
addressed the question whether a change of survivin
status affects the development of radiographic joint
damage. Figure 3A shows the median increase in total
SHS over time in the four survivin groups. The overall
and post hoc analysis between the individual groups re-
vealed that the positive-positive group had a greater in-
crease in SHS than the negative-negative group at 24
and 60 months (both, P = 0.0001). The post hoc pairwise
analyses showed significant differences between the
positive-positive and negative-negative groups (P = 0.001
at 2 years and P < 0.001 at 5 years) and the positive-
negative and negative-negative groups (P = 0.002 at
2 years and P = 0.001 at 5 years). Survivin positivity
both at baseline and after 24 months predictedeasurements of survivin by ELISA. (A) Twenty randomly chosen
and autoantibodies to cyclic citrullinated peptides (aCCPs) were used
F- and aCCP-positive pool (pool C) and a RF- and aCCP-negative pool
ith sample dilution. (B) Pool A (survivin-positive) was diluted with pool
creasing concentrations of RF. (C) A spike recovery procedure whereby
d pool C (RF- and aCCP-positive) were spiked with recombinant
ich was similar for all tested pools.
Figure 3 Survivin positivity is associated with persistent disease activity and progressive joint damage in rheumatoid arthritis patients.
The development of radiographically detected joint damage (assessed by Sharp-van der Heijde score SHS)) (A), Disease Activity Score based on
evaluation of 28 joints (DAS28) (B), functional disability (Stanford Health Assessment Questionnaire (HAQ)) (C) and pain perception (pain scored
on Stanford Visual Analogue Scale (VAS)) (D) are presented in the positive and negative groups for survivin on both occasions (positive-positive
(n = 139) and negative-negative (n = 129)) and for the positive–negative group (n = 53) and negative–positive group (n = 18). There was a signifi-
cant overall difference in SHS between groups at 2 and 5 years (P = 0.001 for both time points). Similarly, overall significant differences in DAS28
scores between groups were observed at 2 and 5 years (P = 0.008 and 0.003, respectively).
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(OR 2.9 (95% CI 1.7 to 5.1), P = 0.001; PPV 0.72 and spe-
cificity 0.75).
Clinical remission and functional disability
The change in DAS28 scores in the four analysed groups
during 60 months of follow-up are presented in
Figure 3B. Because the overall significant differences be-
tween survivin groups, the post hoc analyses between
individual groups were performed. Overall significant dif-
ferences in DAS28 scores between groups was observed at
2 and 5 years (P = 0.008 and 0.003, respectively). Post hoc
comparisons displayed significant differences between the
negative-negative and positive-positive groups at 2 years
(P = 0.04) and at 5 years (P = 0.004).
A univariate analysis of the ability of survivin status to
predict remission at 60 months showed that only survi-
vin negativity both at baseline and at 24 months pre-
dicted remission after 60 months (OR 2.14 (95% CI 1.3to 3.5), P = 0.002; PPV 0.50 and specificity 0.69). After
adjusting for RF, the survivin negativity on both occa-
sions still predicted remission at 60 months (OR 1.99
(95% CI 1.02 to 3.87); P = 0.043). The probability of
achieving remission within 60 months was low in
patients positive for survivin on any test occasion.
Figures 3C and 3D show the development of pain per-
ception (VAS-rated pain) and functional disability (based
on HAQ) in the four survivin groups. No statistically
significant effect of survivin status on these variables
was observed. However, the patients who were positive
for survivin on both test occasions tended to develop
the highest HAQ scores (Figure 3C) and had persistently
high VAS-rated pain (Figure 3D) during the follow-up
period.
Discussion
In this prospective study, we show that the presence of
survivin in patients with early-onset RA is a consistent
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which lead to extracellular accumulation of survivin in
the blood and synovial fluid of RA patients remains elu-
sive. The cells of nontumoural origin, thymocytes and
CD34+ bone marrow stem cells comprise the major nat-
ural pool of survivin. Survivin is preferentially expressed
during mitotic phases of the cell cycle, and its expression
is downregulated at interphase [22]. Deregulation of the
survivin gene in transformed cells results in its overex-
pression at all phases of the cell cycle. Survivin is also
overexpressed in different types of tumours [23]. In RA
patients, survivin is found in the proliferating synovial fi-
broblasts of the lining layer and in the macrophages and T
cells of the inflamed synovial tissue [13-15]. Immunome-
diated destruction of the transformed cells overexpressing
survivin by cytotoxic T cells has been described in patients
with multiple myeloma [24] and neuroblastoma [25],
which may provide a plausible explanation for the extra-
cellular appearance of survivin. Exosomal release of
survivin to the extracellular space has been described pre-
viously [26]. The reproducibility of survivin status in the
consecutive tests in RA patients in the present study sug-
gests that the release of survivin accompanies cellular
events and is associated with clinical disease activity and
radiographically detected joint damage.
The switch of survivin status from positive to negative
that we observed in some of RA patients 24 months
after inclusion into the study could reflect a cessation of
cytolysis due to a regression of inflammation and a re-
version of the pathological process. The initial observa-
tion of an association between survivin and progressive
joint damage in early RA is supported by the data in the
present study, in which the SHS continued to increase
in patients positive for survivin at baseline, regardless of
their later survivin status. In addition, those patients
who converted to survivin positivity after 24 months
tended to display accelerated joint damage later.
The study design permitted only limited analyses of
survivin status with respect to the effect of methotrexate,
sulphasalazine and low-dose prednisolone treatment.
We observed no association between survivin status and
DMARD treatment. No coherence was found between
any of these DMARDs and a survivin switch in the avail-
able patient cohort. The obvious limitation of the study
is the lack of patients treated with biologic drugs, which
are known to efficiently stop disease activity and joint
damage in RA patients resistant to methotrexate treat-
ment [27]. A switch from survivin-positive to survivin-
negative status is expected, followed by arrest of radio-
graphically observed progression.
Intriguingly, survivin is also associated with the pres-
ence of RF and aCCP, the markers of deep changes
in self-recognition in RA patients. The presence of
survivin-specific immune reactions would be expected,owing to intense production of the antisurvivin anti-
bodies measured in RA patients [10], and may be similar
to the mechanisms triggering the production of auto-
antibodies. The high correlation observed between the
presence of autoantibodies (RF and/or aCCP) and survi-
vin obligated us to study the accuracy of survivin mea-
surements in the samples containing RF and/or aCCP.
Three steps of technical evaluation, including dilution-
related recovery and spike recovery procedures, allowed
us to conclude that the presence of autoantibodies is un-
likely to affect the measurement of survivin in the ex-
perimental setting we used. Additionally, the statistical
evaluation proved the independent nature of these pa-
rameters for the prediction of radiologically observed
progression of joint damage.
In this study, survivin was associated with the presence
of aCCP and with smoking history at baseline. This asso-
ciation draws attention to a known predictive value of
smoking for the development of RA ahead of its clinical
symptoms [28,29]. Whether high levels of survivin may
be considered a consequence of smoking is not clear.
We found a recent report of measurements of serum
survivin in patients with non-small cell lung cancer,
among whom 92% were smokers [30]. The study failed
to identify differences in survivin levels between the lung
cancer patients and nonsmoker controls. However, more
studies of this interesting issue must be awaited. Inter-
estingly, the presence of aCCP and smoking was predict-
ive for persistent survivin positivity. aCCP has been
found to be an independent predictor of radiographically
visualised joint damage [7,31] and the efficacy of
DMARD treatment [32] in patients with established RA.
We have previously reported that a combination of sur-
vivin with aCCP and/or RF enhances the predictive
power for the development of joint damage [11]. A mul-
tiple logistic regression analysis revealed survivin as a
factor independent of aCCP for the prediction of radio-
graphically observed joint damage. The evaluation of the
predictive role of survivin for the development of RA
would be a natural next step in understanding the role
of survivin in the pathogenesis of the disease.
Conclusion
Survivin is a relevant and reproducible marker of severe
RA. Survivin positivity on both test occasions was asso-
ciated with smoking and the presence of aCCP and/or
RF antibodies, as well as with persistent disease activity
and joint damage. Survivin may be included in predictive
models for improved treatment decisions for patients
with early RA.
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